PEGylation of paclitaxel largely improves its safety and anti-tumor efficacy following pulmonary delivery in a mouse model of lung carcinoma

Journal of Controlled Release

Volumn 239, Issue , 2016, Pages 62-71

  Luo, Tian ^a,b   Loira Pastoriza, Cristina ^a   Patil, Harshad P ^a   Ucakar, Bernard ^a   Muccioli, Giulio G ^a   Bosquillon, Cynthia ^b   Vanbever, Rita ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Inhaled chemotherapy; Lung cancer; Paclitaxel; Polymer drug conjugates; Prodrug; Pulmonary delivery

Indexed keywords

BIOLOGICAL ORGANS; CHEMOTHERAPY; DISEASES; DRUG INTERACTIONS; DRUG PRODUCTS; ENZYME INHIBITION; MAMMALS; PATHOLOGY; TOXICITY; TUMORS;

LUNG CANCER; PACLITAXEL; POLYMER DRUGS; PRODRUGS; PULMONARY DELIVERY;

DRUG DOSAGE;

CELL ENZYME; LACTATE DEHYDROGENASE; MACROGOL; PACLITAXEL; ANTINEOPLASTIC AGENT; DRUG CARRIER; MACROGOL DERIVATIVE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY ASSAY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RETENTION; DRUG SAFETY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LACTATE DEHYDROGENASE BLOOD LEVEL; LEWIS CARCINOMA; LUNG LAVAGE; MAXIMUM TOLERATED DOSE; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PRIORITY JOURNAL; RETENTION TIME; SINGLE DRUG DOSE; SUSTAINED DRUG RELEASE; WEIGHT REDUCTION; ANIMAL; C57BL MOUSE; CHEMISTRY; PATHOLOGY; PROCEDURES; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, LEWIS LUNG; CELL LINE, TUMOR; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; FEMALE; MICE; MICE, INBRED C57BL; PACLITAXEL; POLYETHYLENE GLYCOLS;

EID: 84983604718     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2016.08.008     Document Type: Article

References (33)

1. [1] Siegel, R.L., Miller, K.D., Jemal, A., Cancer statistics, 2015. CA Cancer J. Clin. 65 (2015), 5–29.
2. [2] Bonfill, X., Serra, C., Sacristan, M., Nogue, M., Losa, F., Montesinos, J., Second-line chemotherapy for non-small cell lung cancer. Cochrane Database Syst. Rev., 2001, CD002804.
3. [3] Torre, L.A., Siegel, R.L., Jemal, A., Lung cancer statistics. Adv. Exp. Med. Biol. 893 (2016), 1–19.
4. [4] Kyle, A.H., Baker, J.H., Gandolfo, M.J., Reinsberg, S.A., Minchinton, A.I., Tissue penetration and activity of camptothecins in solid tumor xenografts. Mol. Cancer Ther. 13 (2014), 2727–2737.
5. [5] Minchinton, A.I., Tannock, I.F., Drug penetration in solid tumours. Nat. Rev. Cancer 6 (2006), 583–592.
6. [6] Patton, J.S., Fishburn, C.S., Weers, J.G., The lungs as a portal of entry for systemic drug delivery. Proc. Am. Thorac. Soc. 1 (2004), 338–344.
7. [7] Zarogoulidis, P., Chatzaki, E., Porpodis, K., Domvri, K., Hohenforst-Schmidt, W., Goldberg, E.P., Karamanos, N., Zarogoulidis, K., Inhaled chemotherapy in lung cancer: future concept of nanomedicine. Int. J. Nanomedicine 7 (2012), 1551–1572.
8. [8] Zarogoulidis, P., Giraleli, C., Karamanos, N.K., Inhaled chemotherapy in lung cancer: safety concerns of nanocomplexes delivered. Ther. Deliv. 3 (2012), 1021–1023.
9. [9] Zarogoulidis, P., Eleftheriadou, E., Sapardanis, I., Zarogoulidou, V., Lithoxopoulou, H., Kontakiotis, T., Karamanos, N., Zachariadis, G., Mabroudi, M., Zisimopoulos, A., Zarogoulidis, K., Feasibility and effectiveness of inhaled carboplatin in NSCLC patients. Investig. New Drugs 30 (2012), 1628–1640.
10. [10] Roa, W.H., Azarmi, S., Al-Hallak, M.H., Finlay, W.H., Magliocco, A.M., Lobenberg, R., Inhalable nanoparticles, a non-invasive approach to treat lung cancer in a mouse model. J. Control. Release 150 (2011), 49–55.
11. [11] Koshkina, N.V., Waldrep, J.C., Roberts, L.E., Golunski, E., Melton, S., Knight, V., Paclitaxel liposome aerosol treatment induces inhibition of pulmonary metastases in murine renal carcinoma model. Clin. Cancer Res. 7 (2001), 3258–3262.
12. [12] Gill, K.K., Nazzal, S., Kaddoumi, A., Paclitaxel loaded PEG5000–DSPE micelles as pulmonary delivery platform: formulation characterization, tissue distribution, plasma pharmacokinetics, and toxicological evaluation. Eur. J. Pharm. Biopharm. 79 (2011), 276–284.
13. [13] Zou, Y., Fu, H., Ghosh, S., Farquhar, D., Klostergaard, J., Antitumor activity of hydrophilic paclitaxel copolymer prodrug using locoregional delivery in human orthotopic non-small cell lung cancer xenograft models. Clin. Cancer Res. 10 (2004), 7382–7391.
14. [14] Kaminskas, L.M., McLeod, V.M., Ryan, G.M., Kelly, B.D., Haynes, J.M., Williamson, M., Thienthong, N., Owen, D.J., Porter, C.J., Pulmonary administration of a doxorubicin-conjugated dendrimer enhances drug exposure to lung metastases and improves cancer therapy. J. Control. Release 183 (2014), 18–26.
15. [15] Loira-Pastoriza, C., Todoroff, J., Vanbever, R., Delivery strategies for sustained drug release in the lungs. Adv. Drug Deliv. Rev. 75 (2014), 81–91.
16. [16] Waite, C.L., Roth, C.M., Nanoscale drug delivery systems for enhanced drug penetration into solid tumors: current progress and opportunities. Crit. Rev. Biomed. Eng. 40 (2012), 21–41.
17. [17] Maeda, H., Nakamura, H., Fang, J., The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Adv. Drug Deliv. Rev. 65 (2013), 71–79.
18. [18] Li, C., Price, J.E., Milas, L., Hunter, N.R., Ke, S., Yu, D.F., Charnsangavej, C., Wallace, S., Antitumor activity of poly(L-glutamic acid)-paclitaxel on syngeneic and xenografted tumors. Clin. Cancer Res. 5 (1999), 891–897.
19. [19] Bayard, F.J., Thielemans, W., Pritchard, D.I., Paine, S.W., Young, S.S., Backman, P., Ewing, P., Bosquillon, C., Polyethylene glycol-drug ester conjugates for prolonged retention of small inhaled drugs in the lung. J. Control. Release 171 (2013), 234–240.
20. [20] Gursahani, H., Riggs-Sauthier, J., Pfeiffer, J., Lechuga-Ballesteros, D., Fishburn, C.S., Absorption of polyethylene glycol (PEG) polymers: the effect of PEG size on permeability. J. Pharm. Sci. 98 (2009), 2847–2856.
21. [21] Danhier, F., Magotteaux, N., Ucakar, B., Lecouturier, N., Brewster, M., Preat, V., Novel self-assembling PEG-p-(CL-co-TMC) polymeric micelles as safe and effective delivery system for paclitaxel. Eur. J. Pharm. Biopharm. 73 (2009), 230–238.
22. [22] Pang, X., Du, H.L., Zhang, H.Q., Zhai, Y.J., Zhai, G.X., Polymer-drug conjugates: present state of play and future perspectives. Drug Discov. Today 18 (2013), 1316–1322.
23. [23] Pasut, G., Veronese, F.M., PEG conjugates in clinical development or use as anticancer agents: an overview. Adv. Drug Deliv. Rev. 61 (2009), 1177–1188.
24. [24] Singla, A.K., Garg, A., Aggarwal, D., Paclitaxel and its formulations. Int. J. Pharm. 235 (2002), 179–192.
25. [25] Quasthoff, S., Hartung, H.P., Chemotherapy-induced peripheral neuropathy. J. Neurol. 249 (2002), 9–17.
26. [26] Carvalho, T.C., Carvalho, S.R., McConville, J.T., Formulations for pulmonary administration of anticancer agents to treat lung malignancies. J. Aerosol Med. Pulm. Drug Deliv. 24 (2011), 61–80.
27. [27] Luo, T., Magnusson, J., Preat, V., Frederick, R., Alexander, C., Bosquillon, C., Vanbever, R., Synthesis and in vitro evaluation of polyethylene glycol-paclitaxel conjugates for lung cancer therapy. Pharm. Res. 33 (2016), 1671–1681, 10.1007/s11095-016-1908-2.
28. [28] Eiseman, J.L., Eddington, N.D., Leslie, J., MacAuley, C., Sentz, D.L., Zuhowski, M., Kujawa, J.M., Young, D., Egorin, M.J., Plasma pharmacokinetics and tissue distribution of paclitaxel in CD2F1 mice. Cancer Chemother. Pharmacol. 34 (1994), 465–471.
29. [29] Klonne, D.R., Dodd, D.E., Losco, P.E., Troup, C.M., Tyler, T.R., Two-week aerosol inhalation study on polyethylene glycol (PEG) 3350 in F-344 rats. Drug Chem. Toxicol. 12 (1989), 39–48.
30. [30] Webster, R., Didier, E., Harris, P., Siegel, N., Stadler, J., Tilbury, L., Smith, D., PEGylated proteins: evaluation of their safety in the absence of definitive metabolism studies. Drug Metab. Dispos. 35 (2007), 9–16.
31. [31] Koussoroplis, S.J., Paulissen, G., Tyteca, D., Goldansaz, H., Todoroff, J., Barilly, C., Uyttenhove, C., Van Snick, J., Cataldo, D., Vanbever, R., PEGylation of antibody fragments greatly increases their local residence time following delivery to the respiratory tract. J. Control. Release 187 (2014), 91–100.
32. [32] Tannock, I.F., Rotin, D., Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res. 49 (1989), 4373–4384.
33. [33] Estrella, V., Chen, T., Lloyd, M., Wojtkowiak, J., Cornnell, H.H., Ibrahim-Hashim, A., Bailey, K., Balagurunathan, Y., Rothberg, J.M., Sloane, B.F., Johnson, J., Gatenby, R.A., Gillies, R.J., Acidity generated by the tumor microenvironment drives local invasion. Cancer Res. 73 (2013), 1524–1535.